TMO
Thermo Fisher Scientific Inc.
September 15, 2026 · market open
- Rarity
- 1.17
- Peak move
- +4.57%
- Float cap
- $230.3B
Thermo Fisher Scientific is the world leader in serving science, providing reagents, instruments, consumables, software, and services used in biological and medical research, drug and vaccine discovery and production, diagnostics, and laboratory workflows. It serves pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, research institutions, government agencies, and environmental, industrial, and quality-control customers through brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 0 from SEC or newswire · 0 timed with the move- Key event
executive_remarkThermo Fisher CEO Marc Casper said in a CNBC interview that AI will spur more pharma R&D spending rather than reduce it, and that Thermo Fisher expects about 4% organic growth in H2 2026, accelerating to 7% by 2028, citing the OpenAI collaboration to speed clinical trials.
product_launchMayo Clinic and Thermo Fisher Scientific launched Precure, LLC on Sept 15, 2026, a Mayo-controlled company to build a multi-omics dataset from one million biospecimens, with Mayo Clinic as majority owner and Thermo Fisher as minority owner contributing its Olink Explore HT and Orbitrap mass spectrometry platforms.
- Key event
spinoff_divestitureThermo Fisher Scientific completed the sale of its microbiology business, which provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing, to private equity firm Astorg for approximately $1.075 billion in cash plus a $50 million seller note.
- Key event
export_controlChina's Ministry of Commerce and General Administration of Customs imposed a temporary export ban on helium, tightening global supply for laboratory instrumentation.
analyst_ratingUBS upgraded Thermo Fisher Scientific to Buy from Neutral and raised its price target to $730 from $540.
executive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, CEO Marc Casper said Thermo Fisher exited Q2 at 5% organic growth with 13% EPS growth, expects about 4% organic growth for full-year 2026 with Pharma Services stepping up in H2 2026, said the Solventum Filtration, Clario and bioproduction acquisitions are performing well, and said he was more bullish on China after a trip.